8 results
In the present study, we aim to estimate concordance between two biomarkers developed to interrogate the presence of brain amyloid deposition. This includes a new amyloid PET-tracer, [18F]Flutemetamol, and a CSF biomarker The objective of the…
Primary objective:1. To investigate the clinical value of [18F]Flutemetamol PET in memory clinic patients and especially those with suspicion of young onset dementia in terms ofa. change in (level of confidence of) diagnosis;b. impact on patient…
To evaluate in a feasibility study whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older AD cohorts apply to the extreme elderly (90+ years old) and to identify novel biomarkers linked with resilience to developing…
To develop a non-invasive algorithm that allows the detection of LRPs with CTCA
To determine the influence of concomitant administration of Lonsurf with metformin and cimetidine on Lonsurf and metformin exposure.
The main objectives are to identify markers for amyloid pathology in cognitively normal subjects, to identify risk factors for amyloid pathology in cognitively normal subjects and to identify predictors for cognitive decline in cognitively normal…
The aim of this study is to evaluate the additional value of quantitative amyloid imaging analysis for modelling and assessing Alzheimer*s Disease (AD) dementia risk in individuals without dementia, compared to a range of existing cognitive, imaging…